Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report.

In metastatic stage, therapeutic approach for malignant melanoma is particularly based on performance status, metastatic sites, and status (/ or (class I mutations). In most cases, mutations and mutations are mutually exclusive to each other. However, some rare mutations class III are preferentially associated with a mutation, leading to the MAP Kinase pathway activation and subsequent cell proliferation.